Article Data

  • Views 4353
  • Dowloads 147

Meeting Abstracts

Open Access Special Issue

Deprescribing is essential for good prescribing

  • Georgia Micha1

1Second Department of Surgery, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece

DOI: 10.22514/sv.2021.193 Vol.17,Issue S1,September 2021 pp.49-49

Submitted: 26 August 2021 Accepted: 06 September 2021

Published: 15 September 2021

*Corresponding Author(s): Georgia Micha E-mail: mgeo3@yahoo.gr

Abstract

In 2017 the World Health Organization recognized the potential patient-related harm of polypharmacy as a matter in need of attendance in the years to come and it was set as a priority in the Medication without Harm Initiative. Polypharmacy is rather common in the elderly patients due to their multimorbidities and in patients with chronic pain. It has been related to drug adverse reactions, increased length of hospital stay, falls and increased morbidity. All these are augmented by the number of different drugs and the nature of the disease. Risk factors of polypharmacy are increasing age, female gender, low educational level and socio-economic status, multimorbidity and number of hospitalizations.

The term deprescribing comes to confront this issue by means of establishing a well designed plan of discontinuing or tapering off drugs that can cause potential harm to the patient. It is based on the principles of revision of all inappropriate drugs, of gradual reduction, dicontinuation or replacement of these drugs, of designing a certain plan of action along with the patients’ education and cooperation. Guidelines already exist for certain kind of drugs (antihypertensives, statins, antipshychotics a, benzodiazepines) with positive outcomes.

In the case of opioid deprescribing in chronic pain management the challenge escalates since there are further issues to be addressed. Opioid withdrawal, the fear of changing the pain management status quo and a level of uncertainty regarding the optimum tapering opioid plan are barriers in the process. Guidelines on opioid deprescribing are in need to address all these matters of concern.


Cite and Share

Georgia Micha. Deprescribing is essential for good prescribing. Signa Vitae. 2021. 17(S1);49-49.

References

[1] WHO. WHO Global Patient Safety Challenge: Medication Without Harm. 2017. Available at: http://www. who. int/ patientsafety/medication- safety/ medication- without- harm- brochure/ en/ (20 July 2020).

[2] Elbeddini A, Sawhney M, Tayefehchamani Y, et al. Deprescribing for all: a narrative review identifying inappropriate polypharmacy for all ages in hospital settings. BMJ Open Quality, 2021; 10: e001509


Submission Turnaround Time

Top